Should You Buy Evogene Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Evogene Ltd. (EVGN) registers a weak Quality of Company score of 2.1/10. At the current price of $0.53, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.
The short answer: 4 of 8 CirclFi valuation models project upside for Evogene Ltd. (EVGN) at $0.53 — the models are evenly split, with a Quality Score of 2.1/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $0.98 (+84.8% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $0.98 (+84.8%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
- Industry tailwind: automation and productivity gains could provide meaningful support for Evogene Ltd.'s revenue and margin trajectory in the Agricultural Chemicals space.
The Bear Case
Target: $0.17 (-68.9%)
- According to the CirclFi Quality of Company (QOC) framework, Evogene Ltd.'s score of 2.1/10 signals fundamental weaknesses that could undermine the investment thesis.
- According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.17 (-68.9%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +153.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
- Industry headwind: raw material cost inflation represents a meaningful risk for Evogene Ltd. and its Agricultural Chemicals peers.
The Bottom Line
Evogene Ltd. at $0.53 is a genuine coin-flip in our framework. The 4–4 bull-bear split across 8 models, +153.7% model spread, and composite fair value of $0.56 (+5.3% avg.) argue for a watchlist position rather than a high-conviction bet. Quality at 2.1/10 adds additional caution to the mix.
These are quantitative model outputs, not investment recommendations. Evogene Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy EVGN stock right now?
Based on CirclFi's multi-model analysis, 4 of 8 models see upside for EVGN at $0.53. The models are divided, which means the investment case depends heavily on your assumptions about Evogene Ltd.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Evogene Ltd.?
Key risks include: a below-average Quality Score of 2.1/10, indicating fundamental weakness; wide model disagreement (495% spread), signaling high uncertainty; general market and sector-specific risks affecting Agricultural Chemicals companies. Always diversify and consult a financial advisor.
How does EVGN compare to its competitors?
Among Agricultural Chemicals peers, EVGN holds a Quality Score of 2.1/10. Comparable companies include CF (QOC 10.0), UAN (QOC 9.1), NTR (QOC 8.0). The relative ranking helps investors identify whether EVGN offers better fundamental quality than alternatives in the same sector.
Is EVGN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. EVGN's Quality Score of 2.1/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy EVGN at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.17 to $0.98. At $0.53, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for EVGN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad